ArticleFrontiers in pharmacology2025
Comparison of the efficacy and safety of low-dose calcineurin inhibitors plus sirolimus plus mycophenolic acid with the standard-dose calcineurin inhibitors plus mycophenolic acid regimen in patients who received kidney transplants.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of mizoribine in renal transplant recipients on calcineurin inhibitor-based immunosuppression: a network meta-analysis.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sirolimus (SRL) has shown its anti-rejection and renoprotective efficacy in patients with kidney transplantation. However, more evidence is still needed. The current study aimed to evaluate the efficacy and safety of an SRL-containing regimen in patients who received kidney transplants. Methods: Fifty patients with end-stage renal disease who received kidney transplants were enrolled and divided into the calcineurin inhibitors (CNI) + mycophenolic acid (MPA)+ glucocorticoid ( Results: The Cr at month (M)6, M12, and uric acid at M3 were lower, while the eGFR at M12 was higher in the CNI + MPA + SRL + glucocorticoid group compared with the CNI + MPA + glucocorticoid group (all Conclusion: Low-dose CNI combined with SRL regimen as the initial anti-rejection regimen indicates a comparable anti-rejection and better renoprotective efficacy with a satisfying safety profile compared with the standard regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.